Golimumab [Simponi]

General Information

Subsidy Information and Financing Scheme

MAF

Golimumab (Simponi) Prefilled Syringe 50 mg/0.5 mL, 100 mg/mL

Additional clinical criteria applies

1) Treatment of adult patients with rheumatoid arthritis
2) T...

Drug Guidance for Subsidy

18/01/2021 Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis

The Ministry of Health’s Drug Advisory Committee has recommended:

Golimumab 50 mg/0.5 ml and...

Post Marketing Information

DHCPL 03/03/2023 SIMPONI (golimumab) 50 mg and 100 mg: Important Changes to the Patient Information Leaflet (PIL) for the SmartJect (pre-filled pen)

General Availability in Public Healthcare Institution
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Please select a product for clinical info:

SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML [SIN16118P]
SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100 MG/1.0 ML (SMARTJECT INJECTOR) [SIN14735P]
SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50 MG/0.5 ML (SMARTJECT INJECTOR) [SIN14105P]
SIMPONI® I.V. CONCENTRATE FOR SOLUTION FOR INFUSION 12.5MG/1 ML [SIN14734P]

Please select a Registered Product for product info.

Golimumab [Simponi]

General Information

Golimumab (Simponi) Prefilled Syringe 50 mg/0.5 mL, 100 mg/mL

MAFGolimumab (Simponi) Prefilled Syringe 50 mg/0.5 mL, 100 mg/mL

Registered Product(s) Information